Document Detail


Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease.
MedLine Citation:
PMID:  8476257     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the Familial Atherosclerosis Treatment Study (FATS), the reduction in clinical events (75%) far outweighed the modest frequency and magnitude of lesion regression observed among those receiving intensive lipid-lowering therapy. To understand this result, the disruptive changes in plaque that trigger clinical events (cardiac death, myocardial infarction, unstable angina) are described. Data are presented in support of the idea that the clinical benefits of lipid-lowering therapy are best explained by stabilization, by depletion of lipid, of the "dangerous" subpopulation of lipid-rich plaques that are often associated with only mild or moderate coronary narrowing.
Authors:
B G Brown; X Q Zhao; D E Sacco; J J Albers
Related Documents :
1835327 - Cholesterol, primary and secondary prevention, and all-cause mortality.
18401237 - Elevated levels of homocysteine predict cardiovascular death, nonfatal myocardial infar...
1642687 - Regression of coronary atherosclerosis by combined ldl-apheresis and lipid-lowering dru...
11481337 - Lipoprotein secretion and triglyceride stores in the heart.
17700397 - Baseline characteristics of patients recruited in the area in-chf study (antiremodellin...
20460497 - Incremental prognostic value of coronary ct angiography in patients with suspected coro...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Annual review of medicine     Volume:  44     ISSN:  0066-4219     ISO Abbreviation:  Annu. Rev. Med.     Publication Date:  1993  
Date Detail:
Created Date:  1993-05-17     Completed Date:  1993-05-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985151R     Medline TA:  Annu Rev Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  365-76     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Washington School of Medicine, Seattle 98195.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use
Coronary Artery Disease / blood,  pathology,  physiopathology,  prevention & control,  therapy*
Coronary Vessels / pathology*
Dietary Fats / administration & dosage
Humans
Lipids / administration & dosage,  blood*
Remission Induction
Grant Support
ID/Acronym/Agency:
R01 HL 19451/HL/NHLBI NIH HHS; R01 HL 30086/HL/NHLBI NIH HHS; R01 HL 42419/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Dietary Fats; 0/Lipids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Special aspects of neuropsychiatric illness in women: with a focus on depression.
Next Document:  Prophylactic antibiotics in surgery.